Video
Dr. Weber on CheckMate-238 Compared With Other Trials in Melanoma
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the results of CheckMate-238 compared with other adjuvant trials for patients with melanoma.
Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the results of CheckMate-238 compared with other adjuvant trials for patients with melanoma.
It is difficult to compare the results of the CheckMate-238 study compared to any other adjuvant study for patients with melanoma, states Weber. Other than the ipilimumab (Yervoy) and nivolumab (Opdivo) study, there are no data to give a frame of reference.
Most adjuvant studies only treat patients with stage IIIa, IIIb, and IIIc melanoma; whereas, in the CheckMate-238 study, it was a group of higher-risk patients, explains Weber.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
